Generic Name and Formulations:
Hydrocodone bitartrate, ibuprofen; 2.5mg/200mg, 5mg/200mg, 10mg/200mg; tabs.
Indications for REPREXAIN:
Short term (generally <10 days) management of acute pain.
Individualize; use lowest effective dose for shortest duration. ≥16yrs: 1 tab every 4–6 hours as needed; max 5 tabs/day.
<16yrs: not recommended.
Aspirin allergy. Coronary artery bypass graft surgery.
NSAIDs may increase risk of cardiovascular thrombotic events, MI, stroke; may be fatal. Advanced renal disease: not recommended. Head injury. Increased intracranial pressure. Acute abdomen. Peptic ulcer. History of upper GI disease/bleed. Impaired renal, hepatic, thyroid, pulmonary, or adrenocortical function. GI or GU obstruction. Asthma. Edema. Hypertension. Heart failure. Coagulation disorders. Monitor BP; hepatic, and renal function (long-term use). Post-op (may suppress cough reflex). Drug abusers. Discontinue if hepatic dysfunction occurs. Elderly. Debilitated. Pregnancy (Cat.C; avoid in 3rd trimester). Labor & delivery, nursing mothers: not recommended.
Avoid aspirin. Additive CNS depression with alcohol, antihistamines, antipsychotics, antianxiety agents, other CNS depressants; reduce dose of either or both drugs if used together. May potentiate, or be potentiated by, MAOIs or tricyclic antidepressants. May increase bleeding with corticosteroids, anticoagulants, smoking, alcohol, long-term NSAID use. Hydrocodone may potentiate skeletal muscle relaxants. May reduce efficacy of, and increase risk of renal failure with, ACEIs, diuretics. Paralytic ileus may occur with anticholinergics. May increase lithium, methotrexate toxicity. Caution with pentazocine, nalbuphine, butorphanol, buprenorphine.
Opioid + NSAID.
Headache, somnolence, dizziness, GI upset/bleed, constipation, edema, rash (discontinue if occurs), anaphylaxis; anemia, respiratory depression, aseptic meningitis (rare); others. See literature re: risk of cardiovascular events.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies